metastatic breast cancer (mBC) and non-small cell lung cancer (NSCLC). WALTHAM, Mass., Feb. 15, 2024 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing ...

WALTHAM, Mass., June 5, 2023 /CNW/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announces the first presentation of its DF1001 TriNKET ...

Dragonfly Therapeutics, Inc. ("Dragonfly"), ... today announced that the first patients have been dosed in the Phase 2 study of its HER2 targeting TriNKET® DF1001.

Since their original 2017 collaboration focusing on hematology malignancies, the companies have agreed to two additional collaborations which include oncology and neuroinflammation targets.

Since their original 2017 collaboration focusing on hematology malignancies, the companies have agreed to two additional collaborations which include oncology and neuroinflammation targets. Today ...

Trodelvy and HER-2 TriNKET combinations will be in metastatic breast cancer (mBC) and non-small cell lung cancer (NSCLC). WALTHAM, Mass., Feb. 15, 2024 /PRNewswire/ -- Dragonfly Therapeutics, Inc ...

Since their original 2017 collaboration focusing on hematology malignancies, the companies have agreed to two additional collaborations which include oncology and neuroinflammation targets. Today ...

Since their original 2017 collaboration focusing on hematology malignancies, the companies have agreed to two additional collaborations which include oncology and neuroinflammation targets. Today ...

In the ASCO Developmental Therapeutics – Immunotherapy Session, Dr. Howard Safran presents encouraging data on Dragonfly's phase 1/2 study of DF1001, an immune engaging TriNKET® targeting HER2 ...

Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies today announced a new clinical collaboration designed to evaluate and combine DF1001, a HER-2 ...

Trodelvy and HER-2 TriNKET combinations will be in metastatic breast cancer (mBC) and non-small cell lung cancer (NSCLC). WALTHAM, Mass., Feb. 15, 2024 /PRNewswire/ -- Dragonfly Therapeutics, Inc ...